AB0341 Favorable Effects of Sirukumab Treatment on Physical Function and Reductions in Morning Stiffness in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Disease-Modifying Anti-Rheumatic Drugs

BackgroundImprovement in physical function and morning stiffness are important goals of rheumatoid arthritis (RA) treatment. Sirukumab, a selective human anti-IL6 monoclonal antibody, has recently been evaluated in a global, Phase 3 study for the treatment of RA in patients (pts) with active disease that did not respond adequately to conventional, synthetic disease-modifying antirheumatic drugs (DMARDs).ObjectivesTo evaluate the effects of sirukumab treatment on physical function and morning stiffness in pts with active RA refractory to DMARDs.MethodsIn this study, eligible pts with active RA and inadequate response to DMARDs were randomized (1:1:1) to treatment with sirukumab SC 50mg q4w, sirukumab SC 100mg q2w, or placebo SC q2w. In the placebo group, pts with insufficient (